Dindaş, FerhatTurgut, Okan OnurYılmaz, Mehmet Birhan2024-10-262024-10-2620201306-76562146-9032https://doi.org/10.5336/cardiosci.2020-75417https://search.trdizin.gov.tr/tr/yayin/detay/382356https://hdl.handle.net/20.500.12418/24951Objective: Today, despite medical developments the frequency of heart failure is increasing. The current guidelines have categorized patients with heart failure (HF) by their phenotypes to betterexplain them. In our study, we aimed to compare the basic clinical features, drug treatment and the life expectancy in HF phenotypes who diedduring hospitalization. Material and Methods: 100 consecutive patientswho admitted with HF between 2011 and 2018 and died of cardiac causeduring last hospitalization were evaluated. Patients with left ventricleejection fraction (LVEF) 41-49% and N-terminal pro-B type natriureticpeptide (NT-proBNP) level >125 pg/mL were classified in the study asHFmrEF. Patients with EF% ?40 NT-proBNP level >125 pg/mL wereclassified in the study as HFrEF. There were 50 patients from each HFgroup. Patients' demographic features, major laboratory parameters, drugtreatments and life expectancy were evaluated in retrospective analysis.SPSS version 17.0 program was used for statistical analysis. p<0.05 wasconsidered statistically significant. Results: The LVEF values of HFrEFand HFmrEF patients were 30% (15-38) and 45% (40-49), respectively.There was no significant difference between groups in drug treatment.The life expectancy values of the groups were 15 (1-61) months in theHFmrEF group and 11 (1-49) months in the HFrEF group (p=0.043).Conclusion: In our study, it was concluded that the demographic characteristics of HFrEF and HFmrEF patients were different. The life expectancy in HFmrEF group was longer than in HFrEF group.en10.5336/cardiosci.2020-75417info:eu-repo/semantics/openAccessArticle3226759382356